Literature DB >> 27884746

Collaborative drug discovery for More Medicines for Tuberculosis (MM4TB).

Sean Ekins1, Anna Coulon Spektor2, Alex M Clark3, Krishna Dole2, Barry A Bunin2.   

Abstract

Neglected disease drug discovery is generally poorly funded compared with major diseases and hence there is an increasing focus on collaboration and precompetitive efforts such as public-private partnerships (PPPs). The More Medicines for Tuberculosis (MM4TB) project is one such collaboration funded by the EU with the goal of discovering new drugs for tuberculosis. Collaborative Drug Discovery has provided a commercial web-based platform called CDD Vault which is a hosted collaborative solution for securely sharing diverse chemistry and biology data. Using CDD Vault alongside other commercial and free cheminformatics tools has enabled support of this and other large collaborative projects, aiding drug discovery efforts and fostering collaboration. We will describe CDD's efforts in assisting with the MM4TB project.
Copyright © 2016 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27884746      PMCID: PMC5362323          DOI: 10.1016/j.drudis.2016.10.009

Source DB:  PubMed          Journal:  Drug Discov Today        ISSN: 1359-6446            Impact factor:   7.851


  92 in total

Review 1.  Collaboration versus outsourcing: the need to think outside the box.

Authors:  Graeme M Robertson; Lorenz M Mayr
Journal:  Future Med Chem       Date:  2011-12       Impact factor: 3.808

Review 2.  Why are membrane targets discovered by phenotypic screens and genome sequencing in Mycobacterium tuberculosis?

Authors:  Robert C Goldman
Journal:  Tuberculosis (Edinb)       Date:  2013-09-18       Impact factor: 3.131

3.  Precarious connections: making therapeutic production happen for malaria and tuberculosis.

Authors:  Susan Craddock
Journal:  Soc Sci Med       Date:  2014-07-17       Impact factor: 4.634

Review 4.  Machine learning applications in genetics and genomics.

Authors:  Maxwell W Libbrecht; William Stafford Noble
Journal:  Nat Rev Genet       Date:  2015-05-07       Impact factor: 53.242

5.  Novel insights into the mechanism of inhibition of MmpL3, a target of multiple pharmacophores in Mycobacterium tuberculosis.

Authors:  Wei Li; Ashutosh Upadhyay; Fabio L Fontes; E Jeffrey North; Yuehong Wang; Debbie C Crans; Anna E Grzegorzewicz; Victoria Jones; Scott G Franzblau; Richard E Lee; Dean C Crick; Mary Jackson
Journal:  Antimicrob Agents Chemother       Date:  2014-08-18       Impact factor: 5.191

6.  Validating new tuberculosis computational models with public whole cell screening aerobic activity datasets.

Authors:  Sean Ekins; Joel S Freundlich
Journal:  Pharm Res       Date:  2011-03-10       Impact factor: 4.200

7.  In vitro and in vivo Evaluation of Synergism between Anti-Tubercular Spectinamides and Non-Classical Tuberculosis Antibiotics.

Authors:  David F Bruhn; Michael S Scherman; Jiuyu Liu; Dimitri Scherbakov; Bernd Meibohm; Erik C Böttger; Anne J Lenaerts; Richard E Lee
Journal:  Sci Rep       Date:  2015-09-14       Impact factor: 4.379

8.  Looking back to the future: predicting in vivo efficacy of small molecules versus Mycobacterium tuberculosis.

Authors:  Sean Ekins; Richard Pottorf; Robert C Reynolds; Antony J Williams; Alex M Clark; Joel S Freundlich
Journal:  J Chem Inf Model       Date:  2014-04-03       Impact factor: 4.956

9.  Predictive modeling targets thymidylate synthase ThyX in Mycobacterium tuberculosis.

Authors:  Kamel Djaout; Vinayak Singh; Yap Boum; Victoria Katawera; Hubert F Becker; Natassja G Bush; Stephen J Hearnshaw; Jennifer E Pritchard; Pauline Bourbon; Peter B Madrid; Anthony Maxwell; Valerie Mizrahi; Hannu Myllykallio; Sean Ekins
Journal:  Sci Rep       Date:  2016-06-10       Impact factor: 4.379

10.  Machine learning models identify molecules active against the Ebola virus in vitro.

Authors:  Sean Ekins; Joel S Freundlich; Alex M Clark; Manu Anantpadma; Robert A Davey; Peter Madrid
Journal:  F1000Res       Date:  2015-10-20
View more
  2 in total

1.  Comparing and Validating Machine Learning Models for Mycobacterium tuberculosis Drug Discovery.

Authors:  Thomas Lane; Daniel P Russo; Kimberley M Zorn; Alex M Clark; Alexandru Korotcov; Valery Tkachenko; Robert C Reynolds; Alexander L Perryman; Joel S Freundlich; Sean Ekins
Journal:  Mol Pharm       Date:  2018-04-26       Impact factor: 4.939

2.  TIBLE: a web-based, freely accessible resource for small-molecule binding data for mycobacterial species.

Authors:  Sony Malhotra; Grace Mugumbate; Tom L Blundell; Alicia P Higueruelo
Journal:  Database (Oxford)       Date:  2017-01-01       Impact factor: 3.451

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.